ALTITUDE SICKNESS

Introduction and Definition

Altitude sickness, also formally termed altitude illness, encompasses a range of adverse health effects that occur following rapid ascent to high terrestrial elevations. This condition is fundamentally a physiological response to hypobaric hypoxia, defined as the reduction in the partial pressure of inspired oxygen ($P_{IO_2}$) caused by decreased atmospheric pressure. While the percentage of oxygen in the air remains constant at approximately 21%, the total number of oxygen molecules available to be inhaled decreases significantly, leading to insufficient arterial oxygen saturation and subsequent tissue hypoxia within the body.

The critical altitude threshold where symptoms commonly begin to manifest is generally considered to be above 2,500 meters (approximately 8,000 feet), although individual susceptibility varies widely based on genetic predisposition, current health status, and most importantly, the rate of ascent. The presentation of altitude illness spans a wide spectrum, ranging from the mild and self-limiting Acute Mountain Sickness (AMS) to the life-threatening conditions of High Altitude Pulmonary Edema (HAPE) and High Altitude Cerebral Edema (HACE). Recognition of early signs is crucial, as delayed intervention can lead to fatal outcomes.

Initial symptoms of exposure often include feelings of queasiness (nausea), headaches, and notable difficulty catching one’s breath, particularly during exertion. More severe manifestations involve significant impairment of neurological function, leading to handicapped cognitive abilities and motor incoordination. While less common, symptoms such as nosebleeds can occur, often linked to dryness, vascular fragility exacerbated by pressure changes, or intense straining associated with coughing. Historically, the visible vascular symptoms led to the common cultural reference to the “nosebleed section” in large venues, associating high elevation or physical strain with minor hemorrhage.

Pathophysiology: The Role of Hypoxia

The immediate physiological challenge at high altitude is the steep drop in the partial pressure of oxygen in the alveoli ($P_{AO_2}$), which drives oxygen into the bloodstream. In response to this decreased oxygen gradient, the body initiates a primary compensatory mechanism: hyperventilation. Peripheral chemoreceptors, primarily located in the carotid bodies, detect the decrease in arterial oxygen content and stimulate an increase in both the rate and depth of respiration, attempting to maintain sufficient oxygen uptake and thus partially restoring $P_{AO_2}$.

While hyperventilation is a necessary adaptation, it introduces a secondary complication: respiratory alkalosis. By increasing the expulsion of carbon dioxide ($CO_2$), the blood carbonic acid concentration decreases, causing the blood pH to rise. This imbalance is addressed by the kidneys, which slowly compensate by increasing the excretion of bicarbonate, a process essential for effective acclimatization. This renal compensation, which may take days, helps normalize the blood pH, thereby allowing the respiratory center to increase ventilation further without the inhibitory effects of alkalosis, marking true acclimatization.

Hypoxia also profoundly affects the cardiovascular system, particularly the pulmonary circulation. Unlike systemic circulation, where hypoxia generally causes vasodilation, hypoxia in the pulmonary system triggers intense, localized pulmonary vasoconstriction. This response is usually adaptive, shunting blood to better-ventilated areas of the lungs. However, at extreme altitudes, this leads to widespread pulmonary hypertension, significantly elevating capillary hydrostatic pressure. This heightened pressure is the mechanical precursor to the fluid leakage into the alveolar space characteristic of HAPE.

In the cerebral circulation, hypoxia initially causes vasodilation to maintain cerebral blood flow (CBF) and ensure adequate oxygen delivery to the brain. This increased volume of blood within the rigid confines of the skull temporarily raises intracranial pressure. When coupled with inflammatory responses and potential disruption of the blood-brain barrier, this pressure increase contributes directly to cerebral edema, which underlies the symptoms of AMS and culminates in the severe neurological deficits observed in HACE, explaining the severe impact on cognitive abilities and coordination.

Clinical Manifestations: The Spectrum of Illness

Altitude illness must be understood as a graded continuum of disease, demanding different levels of urgency and intervention depending on the specific syndrome presented. The key to successful management is differentiating the mild symptoms of AMS from the signs of impending HAPE or HACE. The transition between these states can be rapid, requiring continuous monitoring of individuals who are suffering from moderate or severe AMS, particularly if they continue to ascend or fail to respond to initial treatment protocols.

The mildest and most prevalent form is Acute Mountain Sickness (AMS). Diagnosis requires the presence of a headache, combined with at least one other systemic symptom related to poor appetite, fatigue, dizziness, or sleep difficulty. AMS is fundamentally a reversible condition, and symptoms typically subside within 24 to 48 hours if the individual rests and avoids further ascent, allowing the physiological process of acclimatization to take hold without undue stress.

Progression to High Altitude Pulmonary Edema (HAPE) is signaled by severe respiratory compromise, most notably profound shortness of breath that is disproportionate to the level of exertion, eventually occurring even at rest. A persistent, often wet cough, sometimes producing pink or bloody sputum, is highly indicative of alveolar fluid leakage. HAPE is a medical emergency because the impaired gas exchange rapidly leads to dangerously low systemic oxygen levels, demanding immediate supplemental oxygen and descent to prevent fatality.

High Altitude Cerebral Edema (HACE) represents the severe end of neurological impairment. It is diagnosed when an individual with AMS develops altered mental status, confusion, or the critical sign of ataxia (loss of voluntary muscle coordination). Ataxia can be easily tested by asking the patient to walk heel-to-toe; failure to perform this task is a powerful indicator of significant cerebral swelling. The rapid onset of these neurological signs necessitates immediate, aggressive treatment and emergency evacuation.

Acute Mountain Sickness (AMS)

AMS is the most common altitude-related disorder, affecting a significant percentage of travelers who ascend quickly above 2,500 meters. The onset generally occurs within half a day of arrival at altitude, peaking within the first 24 hours. The defining feature is a headache, which is typically bilateral, frontal, or generalized, often worsening overnight or upon waking. This headache must be accompanied by other manifestations for a formal diagnosis, as outlined by the revised Lake Louise criteria.

The core symptoms of AMS are often grouped into categories. Diagnosis is typically made when a headache is present alongside at least one of the following manifestations:

• Gastrointestinal distress: Including nausea, vomiting, or loss of appetite (queasiness).
• Fatigue or weakness: A general feeling of malaise and lethargy.
• Dizziness or lightheadedness: A sense of unsteadiness.
• Sleep disturbance: Difficulty initiating or maintaining sleep, often related to periodic breathing patterns.

Management of mild AMS focuses on symptomatic relief and preventing progression. This includes remaining at the current altitude, ensuring adequate hydration, avoiding alcohol and sedatives, and using non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, for headache relief. The use of acetazolamide is highly effective, as it accelerates the crucial process of renal compensation, thereby stimulating increased ventilation and hastening acclimatization.

It is paramount that individuals suffering from AMS do not continue their ascent. AMS is reversible with rest at the same altitude, but attempting to ascend further while symptomatic significantly increases the risk of developing the life-threatening complications of HAPE or HACE. If symptoms worsen despite rest, or if they transition into signs of ataxia or severe respiratory distress, immediate descent is the mandatory next step.

High Altitude Cerebral Edema (HACE)

HACE is a rare but lethal consequence of severe, uncorrected altitude illness, representing a profound swelling of the brain tissue. It is characterized by the breakdown of the blood-brain barrier, allowing fluid and protein to extravasate into the interstitial spaces of the brain, a condition termed vasogenic edema. The resulting mass effect causes an acute and dangerous rise in intracranial pressure, leading to neurological compromise.

The clinical picture of HACE is one of worsening AMS transitioning into overt neurological dysfunction. The critical diagnostic signs include severe, unrelenting headache unresponsive to simple analgesics, accompanied by altered mental status—ranging from confusion, memory deficits, and hallucinations to lethargy, stupor, and eventual coma. The single most reliable physical sign indicating HACE is ataxia, demonstrating a clear impairment of balance and coordination that is often missed in the early stages.

The rapid progression of HACE means that it must be treated as an absolute medical emergency. Treatment is centered on two pillars: immediate reduction of cerebral swelling and rapid evacuation. High-dose oral or injectable dexamethasone is the essential medication, as it acts quickly to stabilize cell membranes and reduce edema. However, pharmacological intervention is only a temporizing measure; definitive treatment requires immediate descent to a lower altitude, ideally below the last sleeping altitude where the individual felt well. Supplemental oxygen is also vital to minimize hypoxic damage to the vulnerable brain tissue.

High Altitude Pulmonary Edema (HAPE)

HAPE constitutes the most common fatal outcome of altitude illness. It is a form of non-cardiogenic pulmonary edema driven entirely by the hypoxic environment. Pathophysiologically, HAPE results from an extreme and uneven hypoxic pulmonary vasoconstriction (HPV), leading to excessive pressure in specific pulmonary capillary beds. This high pressure causes sheer stress and damage to the capillary endothelium, resulting in a protein-rich fluid leak into the alveoli, severely impairing gas exchange.

The susceptibility to HAPE is highly individual, and it can affect individuals who have otherwise successfully acclimatized in the past. Symptoms usually manifest 2 to 4 days after arrival at a high altitude. The cardinal sign is severe and disproportionate shortness of breath, initially on exertion but rapidly progressing to dyspnea at rest. Other key indicators include extreme fatigue, chest tightness, and a persistent, worsening cough, which may eventually be productive of pink, frothy sputum.

Diagnosis is primarily clinical, based on the presence of severe dyspnea and signs of fluid in the lungs upon examination (rales or crackles). Treatment for HAPE is complex but non-negotiable: immediate descent is the primary life-saving measure. Concurrent pharmacological therapy involves administering supplemental oxygen and pulmonary vasodilators to reduce the pathological pulmonary artery pressure. Medications such as nifedipine (a calcium channel blocker) or phosphodiesterase inhibitors (e.g., sildenafil) are often used to reverse the excessive pulmonary vasoconstriction, aiding in the resolution of the edema and improving oxygenation until descent can be completed.

Risk Factors and Susceptibility

The single most controllable risk factor for all forms of altitude sickness is the rate of ascent, with rapid travel to elevations above 2,500 meters dramatically increasing incidence rates. However, individual susceptibility plays a major role. A prior history of altitude illness, whether AMS, HAPE, or HACE, is the strongest predictor of future episodes, suggesting underlying genetic or physiological differences in managing the hypoxic challenge. For instance, individuals known to be HAPE-susceptible often exhibit an exaggerated pulmonary hypertensive response to hypoxia.

Certain pre-existing medical conditions also increase risk. Those with pulmonary hypertension, restrictive lung disease, or poorly controlled diabetes may face greater challenges in acclimatizing. Paradoxically, extreme physical fitness does not confer immunity; highly conditioned athletes who push themselves too hard immediately upon arrival at altitude are often among the sufferers, as heavy exertion increases oxygen demand and exacerbates the hypoxic state. Avoiding strenuous activity for the first 48 hours is a critical preventative measure.

Other behavioral factors significantly elevate risk. Dehydration, often compounded by the dry air and increased fluid loss through hyperventilation at altitude, impairs overall physiological function. The consumption of alcohol or sedative medications is particularly dangerous, as these substances suppress the respiratory drive, worsening nocturnal hypoxemia and inhibiting the crucial compensatory mechanisms required for acclimatization. Comprehensive preparation must include addressing these behavioral factors alongside planned gradual ascent.

Prevention and Management Strategies

Prevention relies overwhelmingly on adherence to the principle of gradual ascent. Experts recommend that once travelers are above 3,000 meters (about 10,000 feet), the increase in sleeping altitude should be limited to 300 to 500 meters per day, with a dedicated rest day (no altitude gain) incorporated every three or four days. This slow progression allows the body sufficient time to complete the necessary renal and respiratory acclimatization processes, minimizing the chance of developing AMS or its severe sequelae.

Pharmacological prophylaxis is a key strategy for high-risk individuals or those whose itinerary mandates rapid ascent. Acetazolamide (Diamox) is the preferred drug, typically initiated 24 hours before ascent. It works by inducing a metabolic acidosis, thereby stimulating respiration and improving oxygen saturation during the crucial early phase of acclimatization. For those with known HAPE susceptibility, prophylactic use of pulmonary vasodilators like nifedipine may be warranted, though this requires careful medical supervision.

The definitive management strategy for severe altitude illness operates under the mantra: “Descent, Oxygen, Drugs.” For any suspected case of HACE or HAPE, immediate descent is the most critical and non-negotiable intervention. Even a descent of 500 to 1,000 meters can provide life-saving relief by dramatically increasing the inspired oxygen pressure. Supplemental oxygen, if available, must be administered promptly to stabilize the patient, especially those exhibiting severe respiratory distress or profound handicapped cognitive abilities.

In situations where immediate descent is impossible, such as during extreme weather or in remote locations, a portable hyperbaric chamber (e.g., a Gamow bag) can be used to simulate descent by increasing the ambient pressure around the patient. This provides temporary relief, buying time until definitive evacuation can be organized. Education remains paramount; all travelers must be vigilant for symptoms, particularly the subtle neurological signs like increasing confusion or ataxia, and must be prepared to initiate emergency procedures for themselves or their companions.